Harvard Researchers Unveil Blood Test to Detect Alzheimer’s a Decade Before Symptoms Appear

💛 A quick favor, if you've got a second.

We're really happy that you chose to read one of our stories and sincerely hope you'll stick around to read more. We took our paywall down — for now — but that won't last forever, and when the gate goes back up, we'd love for you to already be on the inside.

It's free. So please enter your email here and don't forget to like and follow us on all of your favorite Social Media platforms!

Share this story:


✉️ Email


💬 Text

Investigators at Harvard have created a blood test that identifies elevated levels of p-tau217, a protein linked to Alzheimer’s disease, potentially allowing physicians to spot individuals at risk for memory loss a decade before symptoms emerge. The findings, published this week in The Journal of the American Medical Association, mark a major breakthrough in early dementia detection and prevention strategies.

The test functions similarly to cholesterol screening for heart disease, offering insights that brain imaging and genetic testing cannot currently provide. Researchers studied approximately 2,700 cognitively healthy older adults averaging 70 years old over a 10-year span to evaluate the biomarker’s predictive value.

Participants with substantially elevated p-tau217 levels showed a 78 percent chance of cognitive impairment within the decade, and a 33 percent risk within five years. Those with moderately high readings faced a 45 percent risk over the same period, according to the research findings.

Harvard Medical School neurology associate professor Rachel Buckley, who led the study, stated that the results demonstrate dementia risk can be assessed years before memory problems develop. She noted that such testing could help researchers identify candidates for clinical trials of preventive treatments and inform future patient monitoring strategies.

Scientists emphasized that p-tau217 levels alone cannot definitively predict dementia, citing age, family history, kidney function, and ethnicity as factors influencing both biomarker readings and disease susceptibility. Researchers called for additional studies involving more diverse populations to enhance predictive accuracy and applicability across different demographic groups.

Maria Carrillo, chief science officer of the Alzheimer’s Association in Chicago, highlighted the value of identifying at-risk patients during early disease stages before cognitive symptoms appear. She stated that early detection enables individuals to explore preventive options during critical intervention windows.

Share this story:


✉️ Email


💬 Text